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Post-kala-azar dermal leishmaniasis (PKDL) is a
cutaneous manifestation of visceral leishmaniasis (VL),
characterized by skin lesions, nodules or papules,
frequently on the face. It often appears 2-7 years after
the apparently successful treatment of VL by antimonial
drugs. It has long been considered a curious
phenomenon, difficult to treat and difficult to explain.
Recent studies have sought to determine parasite, host
and treatment factors that might explain the cause(s) of
PKDL.
First, is there anything special about the parasite?
PKDL is caused by Leishmania donovani in India and
Sudan, with a few cases reported to be caused by L.
infantum / chagasi and historically by either species in
China. Recent molecular studies in India and Sudan on
PKDL and VL clinical isolates have not identified or
defined any strains characteristically associated with
the problem1-3. It seems unlikely to be a parasite
determined manifestation of leishmaniasis. Second, is
there anything different about PKDL patients, their
immunological status, susceptibility or other factors?
Clinical reports have not identified sex, age or racial
origin as defining factors4. A possibility that genetic
disposition might be involved was indicated in Sudan
where genotypic studies identified linkage of the
interferon-γ (IFN-γ) receptor to PKDL and not to VL.
But further studies are required to clearly define
susceptibility factors. The immunological status of
PKDL patients continues to be characterized but the
picture is complex with mixed T cell responses and
elevated levels of interleukin-10 (IL-10) and tumour
necrosis factor alpha (TNF-α)6-9.
The last factor in the puzzle to be considered is
drug treatment. Although there have been reports of
PKDL in untreated patients, the generally accepted view
is that this cutaneous manifestation of VL appears only
after treatment. In their excellent review Zijstra and El-
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Hassan4 (2001) refer to the earliest cases of PKDL
reported in Sudan by Christopherson in 1921 and in
India by Brahmachari in 1922, a time when trivalent
antimonial drugs (for example, antimony tartrate) were
the norm for treatment. The sporadic reports on PKDL
in India and Sudan that were published in the following
decades referred to disease following treatment with
pentavalent antimonials, a form of drug seen now as a
pro-drug for trivalent antimonials10. Is PKDL only
associated with antimonial treatment? In Bihar, India,
amphotericin B has been introduced as a front line drug
following the development of resistance to pentavalent
antimonial treatment. There are now also alternative
treatments for VL in India following the registration of
miltefosine in 200211 and paromomycin in 200612. It is
now possible to test whether PKDL is a specific result
of antimonial treatment. Thakur et al in this issue10
present a retrospective analysis of data on the incidence
of PKDL following the wider use of amphotericin B
and discuss the hypothesis that antimonial treatment
and PKDL are inextricably linked. We know from
recent clinical and experimental studies that sodium
stibogluconate has specific and profound influence on
the immune response through effects on cell signalling,
cytokines and on immune complex induced granulocyte
macrophage colony stimulating factor (GM-CSF)
levels14,15. More importantly, and directly related to
Thakur’s analysis, Saha et al16 have recently reported a
comparative study showing that sodium stibogluconate
and amphotericin B had contrasting effects on IL-10
and transforming growth factor (TGF)-β levels in PKDL
and VL patients, factors already implicated in the
development of this intractable disease.
Further studies are needed to get to the bottom of
the PKDL phenomenon. Prospective clinical trials with
a 2-3 year follow-up are required to really test the
hypothesis that PKDL is a specific sequela of antimonial
treatment. However, the low incidence of PKDL
reported by Thakur et al13 would challenge any trial
design in India. The significantly higher incidence of
PKDL in Sudan makes this the obvious endemic region
to determine the impact of alternative treatments on the
incidence of PKDL. Unfortunately we will have to wait
until miltefosine, paromomycin or AmBisome are
shown to be effective against VL in Sudan before their
impact on PKDL can be investigated. In the meantime,
the elimination of VL is a priority for India, Nepal and
Bangladesh and the accompanying reduction in the
incidence of PKDL will assist this effort by removing a
potential human reservoir.
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